摘要
“Ranibizumab给黄斑变性患者带来了希望”令人惊喜地被美国《科学》杂志评为2006年度十大科学进展之一。Ranibizumab是一种非选择性的血管内皮生长因子抗体。临床研究表明，它不仅使多数患者保持视力稳定，更有约1／3的患者视力得到改善，可有效地治疗渗出型老年性黄斑变性。但对其长期效果仍需进行深入的观察，昂贵的价格也限制了其广泛的临床应用。
＂Ranibizumab bringing a ray of hope for macular degeneration patients＂ was commented as one of the top 10 scientific breakthrough of the year 2006 by Science. Ranibizumab is a recombinant humanized monoclonal anti-vascular endothelial growth factor （VEGF） antibody fragment. The recent results of two clinical trials showed that treatment with the drug ranibizumab improved the vision of roughly one-third of patients with the wet form of age-related macular degeneration （AMD） and stabilizes the condition of most of the others. However, it is necessary to perform further clinical research for evaluating its long-term efficiency. Furthermore, the expensive drug price limits its clinical wide-ranging application.
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2007年第1期1-3,共3页
Chinese Journal of Ocular Fundus Diseases
基金
国家自然科学基金资助项目（30371516,30672291）
教育部留学回国人员科研启动基金资助项目（2004）.
关键词
黄斑变性/治疗
血管内皮生长因子类
抗体
Macular degelleration/therapy
Vascular endothelial growth factors
Antiboclies
